Evidence map›Paper›PMID 27045168›Full record

ArticlePloS one2016

Quantification of Treatment Effect Modification on Both an Additive and Multiplicative Scale.

Nicolas Girerd, Muriel Rabilloud, Philippe Pibarot, Patrick Mathieu, Pascal Roy

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nicolas GirerdINSERM, Centre d'Investigations Cliniques 1433, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.
Muriel RabilloudHospices Civils de Lyon, Service de Biostatistiques, Lyon, F-69003, France, Université de Lyon, Lyon, F-69000, France, Université Lyon I, Villeurbanne, F-69100, France, CNRS, UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistiques Santé, Villeurbanne, F-69100, France.
Philippe PibarotDepartment of Medicine, Laval University, Québec, Canada.
Patrick MathieuDepartment of Surgery, Laval University, Quebec, Canada.
Pascal RoyHospices Civils de Lyon, Service de Biostatistiques, Lyon, F-69003, France, Université de Lyon, Lyon, F-69000, France, Université Lyon I, Villeurbanne, F-69100, France, CNRS, UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistiques Santé, Villeurbanne, F-69100, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn both observational and randomized studies, associations with overall survival are by and large assessed on a multiplicative scale using the Cox model. However, clinicians and clinical researchers have an ardent interest in assessing absolute benefit associated with treatments. In older patients, some studies have reported lower relative treatment effect, which might translate into similar or even greater absolute treatment effect given their high baseline hazard for clinical events.

methodsThe effect of treatment and the effect modification of treatment were respectively assessed using a multiplicative and an additive hazard model in an analysis adjusted for propensity score in the context of coronary surgery.

resultsThe multiplicative model yielded a lower relative hazard reduction with bilateral internal thoracic artery grafting in older patients (Hazard ratio for interaction/year = 1.03, 95%CI: 1.00 to 1.06, p = 0.05) whereas the additive model reported a similar absolute hazard reduction with increasing age (Delta for interaction/year = 0.10, 95%CI: -0.27 to 0.46, p = 0.61). The number needed to treat derived from the propensity score-adjusted multiplicative model was remarkably similar at the end of the follow-up in patients aged < = 60 and in patients >70.

conclusionsThe present example demonstrates that a lower treatment effect in older patients on a relative scale can conversely translate into a similar treatment effect on an additive scale due to large baseline hazard differences. Importantly, absolute risk reduction, either crude or adjusted, can be calculated from multiplicative survival models. We advocate for a wider use of the absolute scale, especially using additive hazard models, to assess treatment effect and treatment effect modification.

Indexed as

Models, TheoreticalTreatment OutcomeAgedCoronary Artery BypassFemaleHumansMaleMiddle AgedSurvival Analysis

Identifiers

PMID27045168
PMCPMC4821587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.